Format

Send to

Choose Destination
Obesity (Silver Spring). 2016 Nov;24(11):2278-2288. doi: 10.1002/oby.21629.

Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.

Author information

1
Scripps Clinic, La Jolla, California, USA. fujioka.ken@scrippshealth.org.
2
Department of Psychiatry and Behavioral Sciences, Weight Management Center, Medical University of South Carolina, Charleston, South Carolina, USA.
3
Department of Health Sciences, Diabetes Research Centre, University of Leicester, Leicester, UK.
4
Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
5
Departments of Medicine, Biochemistry and Molecular Biology, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
6
Novo Nordisk A/S, Søborg, Denmark.
7
Department of Obesity and Endocrinology, University of Liverpool, Liverpool, UK.

Abstract

OBJECTIVE:

To identify an early response criterion for predicting ≥5% weight loss with liraglutide 3.0 mg at week 56 and to compare efficacy outcomes in early responders (ERs) and early nonresponders (ENRs).

METHODS:

Using pooled data from the SCALE Obesity and Prediabetes and SCALE Diabetes trials, weight loss of ≥4% at 16 weeks best predicted ≥5% weight loss after 56 weeks. Weight loss and changes in cardiometabolic risk factors and health-related quality of life were evaluated in ERs (≥4% weight loss at week 16) and ENRs (<4% weight loss at week 16) completing 56 weeks' treatment.

RESULTS:

Proportions of ERs/ENRs to liraglutide 3.0 mg were 77.3%/22.7% (individuals without type 2 diabetes, T2D) and 62.7%/37.3% (those with T2D). Greater mean weight loss was observed in ERs versus ENRs: 10.8% versus 3.0% (without T2D) and 8.5% versus 3.1% (T2D). In both trials, greater proportions of ERs versus ENRs achieved ≥5%, >10%, and >15% weight loss at week 56 with liraglutide 3.0 mg. Greater improvements in cardiometabolic risk factors and health-related quality of life scores were observed in ERs versus ENRs.

CONCLUSIONS:

The early response criterion was clinically useful to identify individuals who would achieve clinically meaningful weight loss at 56 weeks.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01272219 NCT01272232.

PMID:
27804269
PMCID:
PMC5129670
DOI:
10.1002/oby.21629
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center